CClinicalTrials.gg
TerminatedNCT06408649Updated Jul 20, 2025

Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)

An observational study in Ametropia, Myopia and Hyperopia, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Alcon Research · Observational

Why this study was terminated
Management decision
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
129
Ages
7 Years and older
Sex
All
01

Study summary

The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to continuously assess the visual performance and safety of TOTAL30 Sphere and TOTAL30 for Astigmatism contact lenses in a real-world setting across a broad variety of patients through routine clinical practices.

Read the detailed description

The Baseline visit is defined as the first office visit where an eye care professional provided an in-person office biomicroscopy exam to the subject, before or during which a TOTAL30 sphere or toric contact lens prescription was released. Baseline visit data will be collected retrospectively (chart review).

The Year 1 visit is defined as the visit that occurs 1 year (-2/+6 months) since the Baseline visit during which period the subject is wearing test lenses of the same design in both eyes, and a contact lens examination is performed. Year 1 data will be collected either retrospectively or prospectively (eye exam).

02

Conditions studied

  • Ametropia
  • Myopia
  • Hyperopia
  • Astigmatism

Keywords

  • Contact lenses
03

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects will be recruited from clinical sites located in the United States.

Eligibility criteria

Key Inclusion Criteria:

  • Wearers of lehfilcon A (sphere or toric) contact lenses of the same design in both eyes who have already begun use of the lens type and have purchased at least 3-month supply of lenses at the baseline timepoint;
  • Best corrected spectacle visual acuity (VA) 20/25 or better at baseline;
  • Healthy, non-diseased eyes;
  • Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria, as determined or known by the Investigator:

  • Any ocular disease or condition that would contraindicate contact lens wear present at baseline;
  • The use of systemic or ocular medications that would contraindicate contact lens wear at baseline;
  • Participation in a contact lens or contact lens care product clinical trial during the period of the retrospective chart collection or during prospective study participation;
  • Other protocol-specified exclusion criteria may apply.
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
129 participants (actual)
Patient registry
No

Groups and cohorts

  • TOTAL30 Sphere

    Lehfilcon A spherical contact lenses worn in both eyes in a real-world setting

    Device: Lehfilcon A spherical contact lenses

  • TOTAL30 for Astigmatism

    Lehfilcon A toric contact lenses worn in both eyes in a real-world setting

    Device: Lehfilcon A toric contact lenses

Interventions

  • DeviceLehfilcon A spherical contact lenses

    Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)

    Also known as: TOTAL30® Spherical Contact Lenses

  • DeviceLehfilcon A toric contact lenses

    Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism

    Also known as: TOTAL30® for Astigmatism Contact Lenses

05

What researchers measure

Primary outcomes

  1. Distance visual acuity with study lenses at baseline

    Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.

    Time frame: Baseline

  2. Distance visual acuity with study lenses at 1-year follow-up

    Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.

    Time frame: Year 1

  3. Incidence of corneal infiltrative events

    Incidence of corneal infiltrative events occurring after the Baseline Visit will be determined retrospectively (chart review) and prospectively (eye exam).

    Time frame: Up to Year 1

  4. Incidence of microbial keratitis

    Incidence of microbial keratitis occurring after the Baseline Visit will be determined retrospectively (chart review) and prospectively (eye exam).

    Time frame: Up to Year 1

06

Study locations

1 site
  • Contact Alcon Call Center for Trial Locations
    Fort Worth, Texas 76134, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06408649
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Nov 15, 2024
Primary completion
Apr 22, 2025
Completion
Apr 22, 2025
Last update
Jul 20, 2025

Study contacts

Clinical Trial Lead, Vision Care
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion